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Available online xxxxBackground: The TOBY-Xe proof of concept randomised trial found no effect of xenon combined with hypother-
mia after birth asphyxia on the lactate toN-acetyl aspartate ratio (Lac/NAA) in the thalamus and fractional anisot-
ropy (FA) inwhitematter tractsmeasuredwithin 15 days of birth. To conﬁrm that these biomarkers are qualiﬁed
to predict long-term outcome after neural rescue therapy we assessed surviving participants at 2–3 years of age.
Methods: Of the 92 infants in TOBY-Xe, one was omitted from the study, 69 survived and we assessed 62 partic-
ipants, 32 in the hypothermia and xenon and 30 in the hypothermia only groups. We examined the relation be-
tween Lac/NAA and FA and the scores of the Bayley Scales of Infant and Toddler Development III and calculated
their predictive accuracy for moderate or severe disability or death.
Results: Fifteen of 62 participants (24%) developed moderate/severe disability, and 22/92 (24%) died.
The Lac/NAA ratio (difference inmedians 0.628, 95% CI -0.392 to 4.684) and FA (difference inmeans−0.055, 95%
CI -0.033 to−0.077) differed signiﬁcantly between participants with or without moderate or severe disability or
death and were signiﬁcantly related with development scores in both groups. Adverse outcomes were correctly
identiﬁed in 95.65% of cases by Lac/NAA and 78.79% by FA, with adequate mean calibration of the model.
Interpretation: The results conﬁrm the qualiﬁcation of the cerebral magnetic resonance biomarkers employed in
the TOBY-Xe study as predictors of outcome after neuroprotective therapy.
Fund: The Centre for the Developing Brain, King's College London, UK.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Encephalopathy
Asphyxia
Biomarkers
Magnetic resonance spectroscopy
Magnetic resonance tensor imaging
Perinatal brain injury1. Introduction
Xenon, amonoatomic gas that is approved for inhalational anaesthe-
sia, showed promising neuroprotective effects when combined with
moderate hypothermia following asphyxia in studies in animals and in
a preliminary clinical study in adults following cardiac arrest [1–4].
These positive neuroprotective effects are usually attributed to inhibi-
tion of NMDA glutamate receptors and inhibition of apoptotic mecha-
nisms [5,6].
To explore whether inhaled xenon gas combinedwithmoderate hy-
pothermia reduces cerebral injury in near term newborns after birthor the Developing Brain, School
ondon, South Wing, St Thomas'
di).
en access article under the CC BY-NC
hew, A. Deierl, et al., Prospec
://doi.org/10.1016/j.ebiom.20asphyxia, we carried out an open-label, proof of concept, randomised
clinical trial, the TOBY-Xe study (NCT00934700), between 2012 and
2014 [7]. In that study we compared the effects of 24 h of 30% inhaled
xenon combinedwith 72 h of hypothermia to 33.5 °Cwith hypothermia
alone on the lactate to N-acetyl aspartate (Lac/NAA) peak area ratio in
the thalamus measured by proton (1H) magnetic resonance spectros-
copy (MRS) and fractional anisotropy (FA) inwhitematter tracts on dif-
fusion tensor magnetic resonance imaging within 15 days of birth.
These magnetic resonance measures are mechanistically relevant and
clinically prognostic of severe neurological impairment. The Lac/NAA
ratio measured by proton spectroscopy is a bridging biomarker which
detects the effect of neuroprotective therapy in animal studies. Tract
based spatial statistics with diffusion tensor imaging allows statistically
powerful assessment of white matter microstructure, and the separa-
tion of small groups of subjects, thus reducing the sample size signiﬁ-
cantly compared to using visual analysis [8–14]. The TOBY-Xe study-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Research in context
Evidence before this study
We searched Pubmed without language restrictions from 1st Jan-
uary 1990 to 1st January 2019with the terms (xenon AND hypo-
thermia AND outcome) and again with the terms ((magnetic
resonance imaging) OR (magnetic resonance spectroscopy) AND
newborns AND asphyxia AND encephalopathy).
We found just two completed randomised clinical studies of ad-
junct treatment with xenon and hypothermia to prevent brain in-
jury: One was our study in newborns following birth asphyxia
(The TOBY-Xe study); the otherwas in adults following out of hos-
pital cardiac arrest. Both studies used magnetic resonance bio-
markers for early therapeutic assessment. In the study in adults,
global cerebral fractional anisotropy (FA) on magnetic resonance
tensor imaging was slightly preserved in the xenon plus hypother-
mia group compared to the hypothermia only group, but clinical
outcomes assessed six months later were similar in both groups.
Several single centre studies and one largemulticentre prospective
study assessed brain injury following neonatal encephalopathy by
magnetic resonance spectroscopy and/or tensor imaging. In these
studies, the thalamic peak area lactate/ N-acetyl aspartate (Lac/
NAA) ratio and the NAA metabolite concentration were reported
to be the optimal predictors of neurodevelopmental outcome at
2–3 years but no study has prospectively qualified these bio-
markers for rapid assessment of adjunct neural rescue therapy
with hypothermia following birth asphyxia.
Studies in animals using a perinatal asphyxia model assessed po-
tential neural rescue therapies including therapies adjunct to mod-
erate hypothermia using magnetic resonance techniques. In such
studies the Lac/NAA ratio is an excellent biomarker of the thera-
peutic effect and consistently associated with the number of
dead cells on brain immunohistochemistry and with the recovery
of neurophysiological status after hypoxia ischaemia.
Added value of this study
The present study aimed to confirm prospectively the qualification
of the thalamic Lac/NAA ratio and FA in the posterior limb of the
internal capsule after an adjunct neuroprotective treatment with
therapeutic hypothermia after birth asphyxia and neonatal enceph-
alopathy. The study confirmed the high accuracy of the cerebral
biomarkers chosen in the TOBY-Xe study for predicting
neurodevelopmental outcome following birth asphyxia in each
treatment group, and supports their use to evaluate a therapeutic
effect on clinical outcomes, and estimate the power of the study
to detect clinically significant changes in the cerebral biomarkers.
Implications of all the available evidence
Clinical trials of neuroprotective therapies initiated very soon after
birth with clinical outcomes require large numbers, have a long du-
ration and are costly. Statistically powerful qualified biomarkers
measured soon after cerebral injury could enable rapid assessment
of potential therapies in proof of concept studies. The present re-
sults confirm that cerebral magnetic resonance biomarkers, such
as used in our study, provide a rapid and accurate surrogate out-
come that can be used to identify useless interventions early and
select promising neuroprotectants for further study.
2 D. Azzopardi et al. / EBioMedicine xxx (2019) xxxfound no evidence of an effect of xenon combinedwith hypothermia on
the cerebral biomarkers and on other outcomes assessed in the neonatal
period. We concluded that the results did not support carrying out aPlease cite this article as: D. Azzopardi, A.T. Chew, A. Deierl, et al., Prospec
treatment with xenon..., EBioMedicine, https://doi.org/10.1016/j.ebiom.20large deﬁnitive clinical trial of treatmentwith xenon combinedwith hy-
pothermia after birth asphyxia.
Cerebral magnetic resonance biomarkers have not previously been
used prospectively as the primary outcomes in randomised trials of po-
tential neuroprotective therapies following birth asphyxia and neonatal
encephalopathy. Therefore, to conﬁrm that these biomarkers are quali-
ﬁed to predict long-term outcome after neural rescue therapy we
followed up surviving TOBY-Xe participants and performed neurodev-
elopmental assessment at 2–3 years of age. We hypothesized that
there would be concordance between the early cerebral biomarkers
and later neurodevelopmental outcome, and thus no differences on
neurodevelopmental assessment between the two treatment groups.2. Methods
The study was carried out in London, UK at Queen Charlotte
and Chelsea Hospital, University College Hospital and the Evelina
London Children's Hospital. The UKNational Research Ethics Service ap-
proved the study (15/SC/0201) and the study registry identiﬁer is
NCT03968861.
The TOBY-Xe study was carried out from Jan 31, 2012, to Sept 30,
2014.We enrolled 92 infants: 46 infants randomly assigned to standard
care including hypothermia to 33.5o C for 72 h and 46 infants to 30%
xenon for 24 h, started immediately after randomisation in the ﬁrst
12 h after birth, combined with hypothermia. Infants were eligible if
their gestational age was 36–43 weeks and they had at least one of
the following: Apgar score of 5 or less 10 min after birth; continued
need for resuscitation, including endotracheal or mask ventilation,
10 min after birth; or acidosis (deﬁned as pH b 7 or base deﬁcit
N15 mmol/L, or both in umbilical cord blood or any blood sample)
within 1 h of birth. Furthermore, eligible infants showed signs of mod-
erate to severe encephalopathy, consisting of altered state of conscious-
ness (reduced or absent response to stimulation), hypotonia, and
abnormal primitive reﬂexes (weak or absent suck or Moro response),
and had moderately or severely abnormal background activity for at
least 30 min or seizures as shown by amplitude-integrated EEG
(aEEG). We excluded infants if cooling was started after 6 h from birth
or if they were older than 12 h at randomisation.
Magnetic resonance scans were carried out in TOBY-Xe participants
within 15 days of birth. Details of the scanning procedures and the var-
ious sequences used in the TOBY-Xe study have been reported previ-
ously [7]. All MRS and MRI studies were done with 3·0 Tesla systems
(Philips Healthcare, Best, Netherlands) at each centre. The trial research
physicist undertook rigorous standardisation and a quality-control pro-
gramme with phantoms and repeated scanning. Comparability test ob-
jects were transported from site to site during the project. An adult
volunteer was imaged at each site periodically to provide direct com-
parison data. Images were obtained according to a standard protocol
that included diffusion tensor MRI with 32 non-collinear directions,
MRS from a single voxel on the left thalamus, and motion tolerant T1
and T2 structural scans. Tract based spatial statistics controlling for
post menstrual age was used to assess diffusion tensor data for FA
values. Total examination time for the study protocol was around 1 h.
Parents who consented for follow-up were invited to bring their
child back for a neurodevelopmental assessment at 2 years of age. A
paediatrician, trained in performing neurodevelopmental assessments
and unaware of treatment allocation in the TOBY-Xe study, carried out
neurodevelopmental assessments in participants at each of the three
sites (AD at theQueen Charlotte and Chelsea Hospital, AH at the Univer-
sity College Hospital and AC at the Evelina London Children's Hospital)
using the Bayley Scales of Infant and Toddler Development III [15]. AC
contacted the parents of 13 children that could not be examined by
their local hospital paediatrician and, with the parents' consent, carried
out the assessment at the participants' homes, with their parents
present.tive qualiﬁcation of early cerebral biomarkers in a randomised trial of
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Fig. 1. Patient ﬂow in study.
Table 1
Baseline clinical features.
2–3-year outcomes available 2–3-year outcomes not
available
Xenon plus
hypothermia
Hypothermia only All infants All infants
N = 32 N = 30 N = 62 N = 7
Treatment hospital, n (%):
University College London 9 10 19 3
St Thomas' 12 11 23 3
Queen Charlotte and Chelsea 11 9 20 1
Birth in treatment centre, n (%): 12 (38) 10 (33) 22 (35) 1 (14)
Male sex, n (%): 19 (59) 12 (40) 31 (50) 3 (43)
Birth weight (grams):
Mean [SD] 3417 [646] 3265 [492] 3344 [577] 3119 [406]
Gestation at delivery (weeks):
Mean [SD] 39.9 [1.7] 39.8 [1.4] 39.8 [1.6] 40.4 [0.9]
Apgar at 10 minutes:
Median (IQR) 5 (4 to 6.5) 5 (3 to 7) 5 (4 to 7) 4 (1 to 8)
Unknown 4 7 11 0
Cord/ﬁrst blood pH:
Median (IQR) 6.9 (6.8 to 7.1) 6.9 (6.8 to 7.2) 6.9 (6.8 to 7.1) 6.9 (6.7 to 7.0)
Mean [SD] 7.0 (0.2) 6.9 (0.2) 7.0 (0.2) 6.9 (0.2)
Unknown 0 1 1 0
Base Excess (mmol/L):
Median (IQR) –16.8 (–19.1 to –13.5) –16.4 (–22.9 to –11.1) –16.6 (–19.8 to –12.2) –22.1 (–26.5 to –19.7)
Unknown 2 4 6 0
Moderate or severe encephalopathy at trial entry n (%): 32 (100) 30 (100) 62 (100) 7 (100)
Thompson hypoxic ischemic encephalopathy score at trial entry, n (%):
0–10 5 (16) 2 (7) 7 (11) 0 (11)
11–14 19 (59) 21 (70) 40 (65) 5 (57)
15–22 8 (25) 7 (23) 15 (24) 2 (43)
Median (IQR) 13 (11 to 14.5) 13 (11 to 14) 13 (11 to 14) 14 (13 to 15)
Abnormality on aEEG at trial entry, n (%):
Moderate 6 (19) 6 (20) 12 (19) 1 (14)
Severe 26 (81) 24 (80) 50 (81) 6 (86)
Age cooling commenced (hours), n (%):
0 to 4 hours 27 (90) 25 (89) 52 (90) 7 (100)
4 to 6 hours 3 (10) 3 (11) 6 (10) 0 (0)
Median (IQR) 0.2 (0.1 to 2.8) 0.4 (0.1 to 0.9) 0.4 (0.1 to 1.8) 0.2 (0.1 to 3.0)
Unknown 2 2 4 0
Head circumference at admission to neonatal unit (cm):
Mean [SD] 34.3 [1.4] 34.6 [1.6] 34.5 [1.5] 34.4 [1.2]
Unknown 11 6 17 2
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Table 2
Neurodevelopmental outcomes at age 2–3 years.
Xenon plus
hypothermia
Hypothermia
only
Difference in
Medians
(95% CI)
P value
Developmental
score⁎
N= 32 N= 30
Cognitive,
Median (IQR)
90 (67.5 to 100) 90 (75 to 95) 0 (0 to 5) P = .826
Language,
Median (IQR)
92.5 (62 to 104.50) 91 (77 to 100) 1.5 (0 to 3) P= .989
Motor, Median
(IQR)
97 (64 to 103) 94 (67 to 100) 3 (0 to 8) P= .874
Optimality
score
N= 23 N= 22
Median (IQR) 71
(66 to 73)
70.5
(60.50 to 76)
0.5 (2 to 0) P = .794
GMFCS N = 32 N= 30
Level 1–2, n (%) 2 (6.25) 5 (16.67)
Level 3–5, n (%) 6 (18.75) 3 (9.38) RR (95% CI)1 1.875
(0.514 to
6.834)
MACS N = 32 N= 30
Level 1–2, n (%) 2 (6.25) 6 (20)
Level 3–5, n (%) 6 (18.75) 2 (6.67) RR (95% CI)2 2.813
(0.615 to
12.871)
Disability N = 32 N= 30
Mild, n (%) 3 (9.38) 5 (16.67)
Moderate, n (%) 2 (6.25) 3 (9.38) RR (95% CI)3 1.071
(0.443 to
2.593)
Severe, n (%) 6 (18.75) 4 (13.33)
⁎ One child in each allocation group was tested byWPPSI-III. Their scores were: Verbal
IQ 101 and 84; Performance IQ 84 and 100; Full scale IQ 90 and 89. All other participants
were tested using the Bayley-III Scales.
1 Relative risk for GMFCS level 3–5.
2 Relative risk for MACS level 3–5.
3 Relative risk for moderate/severe disability.
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original study due to incomparablemagnetic resonance scanner param-
eters. Of the other 91 newborns recruited, 20 had died in the neonatal
period and one at four months and one at seven months after birth.
Two participants had left the country and 5 parents declined follow-
up assessment. Finally, developmental assessments were conducted in
62 of 69 (90%) surviving children (Fig. 1 – Patient ﬂow).
Sixty participantswere assessed using the Bayley Scales of Infant and
Toddler Development III and two participants older than 3.5 years were
assessedusing theWechsler Preschool and Primary Scale of Intelligence,
WPPSI-III [16]. Neurological assessmentwas by theHammersmith Neu-
rological Examination, reported asOptimality scores (maximumscore is
78) [17]. Clinical signs of cerebral palsy were recorded and classiﬁed ac-
cording to topographical distribution of the Surveillance of Cerebral
Palsy in Europe classiﬁcation. Functional classiﬁcation was scored
based on the Gross Motor Function Classiﬁcation System (GMFCS)
[18], while upper limb function was classiﬁed using the Manual Ability
Classiﬁcation System (MACS) [16]. We also collected clinical informa-
tion regarding health and wellbeing since hospital discharge, including
data on vision, hearing, and seizures, and medications.
2.1. Qualiﬁcation of early cerebral biomarkers with neurodevelopmental
outcomes
We examined the relation between the Lac/NAA in the thalamus
measured by 1H MRS and FA in white matter tracts on diffusion tensor
magnetic resonance and the composite scores of the Cognitive, Lan-
guage and Motor scales in surviving participants, and we calculated
their predictive accuracy for moderate or severe disability or death.
The grade of disability was categorised as mild disability (a CognitivePlease cite this article as: D. Azzopardi, A.T. Chew, A. Deierl, et al., Prospec
treatment with xenon..., EBioMedicine, https://doi.org/10.1016/j.ebiom.20score of 70 to 84, level 1 gross motor function [is able to walk indepen-
dently but may have some gait abnormalities], or abnormality in one or
both eyes with normal or nearly normal vision), moderate disability (a
Cognitive scale score of 56 to 69, level 2 or 3 gross motor function [has
minimal ability to perform gross motor skills or requires assistance
with walking], or moderately reduced vision), or severe disability (a
Cognitive scale score of 55 (theminimum score on the Bayley-III Cogni-
tive scale), level 4 or 5 gross motor function [needs adaptive seating or
has severely limited mobility], or no useful vision).
2.2. Statistical analysis
Stata (version 11) statistical software was used for the statistical
analysis.
Assessment of the relationship between early cerebral biomarkers and
neurodevelopmental outcome: Lac/NAA values were skewed so we
used the natural logarithm,where appropriate.We performed linear re-
gression to assess the relation between the Lac/NAA peak area ratio in
the thalamus and FA in the posterior limb of the internal capsule to
the cognitive, language and motor scale development scores, in the
whole study population and by treatment subgroup. We included in
the analyses the Full IQ, Verbal and Performance scores of the two chil-
dren that were assessed by theWPPSI-III, as these scores have the same
mean and standard deviation as those of the Bayley-III scales. We com-
paredmean ormedian values of the biomarkers in the normal outcome/
mild disability group and the group with moderate or severe disability
or death. We analysed the receiver operating characteristic curve
(ROC) and calculated the area under the curve (AUC), sensitivity, spec-
iﬁcity, and likelihood ratios of the prediction by Lac/NAA and FAofmod-
erate or severe disability, and repeated the analysis including deaths in
the adverse outcome group. We assessed mean calibration of the pre-
diction models by the Hosmer-Lemeshow test.
In the TOBY-Xe study, the Lac/NAA ratioswere not corrected for post
menstrual age at scan, therefore, we tested for a relation between these
measures by linear regression.
Analyses of clinical data of participants: Since all continuous outcomes
had non-Gaussian distributions, we present the median and interquar-
tile range and the difference in medians with 95% conﬁdence intervals
between participants in the xenon combinedwith hypothermia and hy-
pothermia only group.Wilcoxon rank-sum test was used to test the null
hypothesis.We calculated relative risks and95% conﬁdence intervals for
categorical outcomes between the two groups.
3. Results
The clinical characteristics at birth of the study infants are shown in
Table 1, and the results of the key clinical outcomemeasures in Table 2.
The results of the developmental and neurological assessments were
similar in the the xenon/hypothermia (Xe+) and hypothermia only
group (Xe-) group. Twelve of 46 participants (26.08%) from the Xe
+ group and 10/46 (21.74%) from the Xe- group died (Relative risk:
1.2, 95% conﬁdence interval (CI) 0.577 to 2.498). Twenty of the 22
deaths occurred in the neonatal period and the other two deaths oc-
curred at 4 and 7 months of age. The median (IQR) age when develop-
mental assessment was completed was similar in both groups:
Median (IQR) 25.10 (24.43 to 28.58) months in the Xe + group, and
Median (IQR) 25.00 (24.29 to 29.52) months in the Xe- group (Differ-
ence in Medians, 0.10, 95% CI, 0.214 to 2.854).
Relationship between early cerebral biomarkers and neurodev-
elopment: The Lac/NAA ratio in the thalamus and FA in the posterior
limb of the internal capsule measured within 15 days of birth were sig-
niﬁcantly relatedwith the composite cognitive, language andmotor de-
velopmental scores assessed at 2–3 years of age in thewhole population
and in each treatment group (Fig. 2, Table 3). The relation between the
biomarkers and the developmental scale scores appeared to tail off at
low values of the developmental scores, probably due to the ﬁxedtive qualiﬁcation of early cerebral biomarkers in a randomised trial of
19.08.034
Fig. 2. Plot of Log Lac/NAA (N= 57) and FA (N= 56) with cognitive, language and motor developmental scores.
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function described the relationship reasonably well. Using a quadratic
term in the regression did not improve the line of best ﬁt. Excluding
the data from the two infants assessed by WPPSI-III did not materially
change the result of the analyses.
The Lac/NAA ratio and the FA values differed between the normal
outcome/mild disability andmoderate/severe disability or death groups
(Fig. 3 and Table 4). Bothmeasures also accurately predicted moderate/Table 3
Regression coefﬁcients from the association of Lac/NAA ratios and FAwith developmental
scores.
Coefﬁcient (95%CI) r2 P value
Cognitive
Log Lac/NAA Slope −13.345 (−17.381 to−9.308) 0.444 b0.001
Intercept 61.927 (53.636 to 70.216)
Fractional
Anisotropy
Slope 195.728 (105.935 to 285.521) 0.263 b0.001
Intercept 7.432 (−29.420 to 44.286)
Language
Log Lac/NAA Slope −15.365 (−20.403 to −10.328) 0.400 b0.001
Intercept 60.582 (50.238 to 70.926)
Fractional
Anisotropy
Slope 259.991 (158.404 to 361.578) 0.332 b0.001
Intercept −16.291 (−57.976 to 25.393)
Motor
Log Lac/NAA Slope −18.305 (−22.946 to−13.664) 0.548 b0.001
Intercept 54.791 (45.608 to 63.976)
Fractional
Anisotropy
Slope 262.600 (167.067 to 358.133) 0.374 b0.001
Intercept −19.764 (−59.034 to 19.506)
Please cite this article as: D. Azzopardi, A.T. Chew, A. Deierl, et al., Prospec
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were included in the adverse outcome group (Fig. 4 and Table 5). The
Hosmer-Lemeshow goodness of ﬁt test of the predictive models using
all observations in the data indicated adequate mean calibration (P =
.144 for Log Lac/NAA, P= .678 for FA and P= .483 for Lac/NAAplus FA).
There was no correlation between the Lac/NAA ratios and post men-
strual age at scan (P= .272, r2 0.020, Fig. 5).4. Discussion
The Lac/NAA ratio in the thalamus and FA in the posterior limb of the
internal capsule measured within 15 days of birth were highly corre-
lated with neurodevelopmental outcomes and accurately predicted
the occurrence ofmoderate or severe disability in the surviving children
or death in each randomised group. The results conﬁrm thequaliﬁcation
of the cerebral magnetic resonance biomarkers employed in the TOBY-
Xe study as predictors of outcome after neuroprotective therapy follow-
ing birth asphyxia.
Recent studies conﬁrmed the accuracy of MRS and MRI biomarkers
for predicting an adverse outcome following birth asphyxia and neona-
tal encephalopathy, but without testing any therapeutic intervention.
(10;11) The present study thus aimed to conﬁrm prospectively the
qualiﬁcation of the cerebral biomarkers after an adjunct neuroprotec-
tive treatment with therapeutic hypothermia. Studies in animals have
shown that the thalamic Lac/NAA ratio is a sensitive biomarker of the
therapeutic and biological effects of hypothermia and of adjunct treat-
ment with hypothermia following asphyxia, and we have previouslytive qualiﬁcation of early cerebral biomarkers in a randomised trial of
19.08.034
Fig. 3.Plot of log Lac/NAA (N=69) and FA (N=66) values and outcomeat 2–3 years of age by treatment group. Twogroup t-test ofmeansof Lac/NAA on the log scale, in normal outcome/
mild disability and moderate/severe disability/deaths groups in Xe + group, P b .001and Xe- groups, P b .001; Two group t-test of means of FA, in normal outcome/mild disability and
moderate/severe disability/deaths groups in Xe+, P b .001and Xe- groups, P b 0.001.
6 D. Azzopardi et al. / EBioMedicine xxx (2019) xxxshown the value of MR imaging as a biomarker after therapeutic hypo-
thermia in a retrospective analysis of the TOBY randomised trial of ther-
apeutic hypothermia [19–22]. In such studies, using MRS sequences at
3 T similar to those in babies with neonatal encephalopathy, Lac/NAA
is consistently associatedwith the number of dead cells on brain immu-
nohistochemistry and with the recovery of aEEG after hypoxia ischae-
mia. Translating these pre-clinical data to the clinical TOBY-Xe study
gives us conﬁdence in Lac/NAA to detect a biological effect or not as is
the case here with the addition of xenon to hypothermia. Such studies
show that the Lac/NAA ratio is robust enough to clearly demonstrate a
biological effect if it existed. The TOBY-Xe study failed to show a thera-
peutic effect of adjunct treatment with xenon in neonatal encephalopa-
thy, and our results conﬁrm that the cerebral biomarkers do not detect
an effect that is not real. Our results demonstrate the high predictive ac-
curacy of the cerebral biomarkers in both randomised groups. Our data,
together with the data from pre-clinical and clinical observational stud-
ies show that the cerebral biomarkers chosen in the TOBY-Xe study are
accurate in predicting later outcomes following neural rescue therapy,
supporting their use to assess a therapeutic effect on clinical outcomes
in the two outcome groups, and estimate the power of the study to de-
tect clinically signiﬁcant changes in the cerebral biomarkers.Table 4
Biomarker values in infants with and without disability.
Normal outcome/minor disability Moderate/severe disabilit
Lac/NAA N= 45 N= 12
Arithmetic mean (SD) 0.136 (0.067) 0.816 (1.13)
Coefﬁcient of variationa 0.654 1.351
Median [IQR] 0.142 [0.080 to 0.185] 0.600 [0.237 to 0.774]
Fractional Anisotropy N= 44 N = 12
Arithmetic mean (SD) 0.422 (0.034) 0.354 (0.051)
Coefﬁcient of variationb 0.080 0.144
Median [IQR] 0.420 [0.403 to 0.445] 0.358 [0.310 to 0.402]
⁎ Difference between the moderate/severe disability and deaths group and the normal outc
a This is sqrt(exp(var)-1) where var. is the variance on the log scale.
b This is the ratio of the standard deviation to the arithmetic mean in the original untransfo
1 Two group t-test of means of Lac/NAA on the log scale, in normal outcome/mild disability
2 Wilcoxon rank-sum test, in normal outcome/mild disability and moderate/severe disabilit
3 Two group t-test of means of FA, in normal outcome/mild disability and moderate/severe
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in the thalamus was the optimal predictor following neonatal encepha-
lopathy, but another recent study reported a similar predictive accuracy
for the thalamic Lac/NAA ratio [11]. The predictive performance of the
Lac/NAA ratio in our study was nearly identical to that reported in the
MARBLE study when deaths are included in the adverse outcome
group (AUC 0.94, 95% CI 0.866–1.000 in MARBLE and AUC 0.938, 95%
CI 0.866–1.000 in this study). The data are thus consistent. In the
MARBLE study thalamic metabolite concentrations were obtained in
43% of participants, and peak area thalamic metabolite ratios in 84% of
infants. Ourmulticenter study using purposely developed scanning pro-
tocols and compatible scanners acquired peak area thalamic metabolite
ratios from all 78 infants who had an MRI scan in the neonatal period
and FA data from 73/78 (95%) infants, proving the feasibility of using
these biomarkers in clinical trials.
Although standard magnetic resonance imaging with visual assess-
ment is now commonly used to assess the severity of cerebral injury
and guide management following birth asphyxia and neonatal enceph-
alopathy, the high accuracy for predicting later neuro-developmental
outcome and the feasibility of measuring the Lac/NAA ratio on 1H MRS
conﬁrmed in this study indicate that this is potentially a clinically usefuly Moderate/severe disability and deaths Difference (95% CI)⁎ P value
N= 26
1.287 (1.500) 1.151 (1.59 to 0.707) P b .0011
1.462
0.770 [0.392 to 1.575] 0.628 (−0.370 to 4.684) P = .0052
N = 22
0.368 (0.055) −0.055 (−0.033 to−0.077) P b .0013
0.149
0.382 [0.328 to 0.401] −0.038 (−0.09 to−0.053) P b .0012
ome/minor disability group.
rmed data.
and moderate/severe disability/deaths groups.
y/deaths groups.
disability/deaths groups.
tive qualiﬁcation of early cerebral biomarkers in a randomised trial of
19.08.034
Fig. 4. Receiver operating characteristic curves of Lac/NAA ratio (N= 69) and FA (N= 66) and the combination of Lac/NAA and FA (N= 63) for predicting moderate/severe disability/
deaths at 2–3 years.
7D. Azzopardi et al. / EBioMedicine xxx (2019) xxxmeasure that could be incorporated into clinical practice. However,
since 1H MRS studies in newborns have been in specialist centres, fur-
ther clinical studies are needed to determine the feasibility and cost/
beneﬁts of introducing this measure routinely in infants with neonatal
encephalopathy.
Two infants, one from each allocation group, had zero Lac/NAA
values on proton MRS, and both infants developed severe disabilities.
Absence of a lactate signal following severe asphyxial encephalopathy
is highly unusual andwe cannot exclude that the infants had an alterna-
tive pathology. These two data points are dropped following log normal
transformation as log normal transformation of zero values is not
possible.
Studies in animals have suggested that there are several potential
neuroprotectants that might augment the modest therapeutic effect of
moderate hypothermia followingbirth asphyxia. However, clinical trials
of adjunct neuroprotective therapies initiated very soon after birth with
clinical outcomes require large numbers, have a long duration and are
costly. There is a critical need for statistically powerful qualiﬁed bio-
markersmeasured soon after cerebral injury for rapid assessment of po-
tential therapies in proof of concept studies. The present results conﬁrmTable 5
Predictive accuracy of early cerebral biomarkers for moderate/severe disability or death at 2–3
Participating survivo
Correctly classiﬁed (%), [cutpoint] AUCa (95% CI)
Lac/NAA (N= 57) 91.53 [≥0.308] 0.752 (0.548 to 0.9
FA (N = 56) 87.50 [≤0.363] 0.877 (0.773 to 0.9
Lac/NAA + FA (N= 52) 94.20 [≥0.591] 0.914 (0.807 to 1.0
Participants inclu
Lac/NAA (N= 71) 95.65 [≥0.308] 0.938 (0.866 to 1.0
FA (N = 66) 78.79 [≤0.403] 0.818 (0.703 to 0.9
Lac/NAA + FA (N = 63) 93.65 [≥0.611] 0.955 (0.903 to 1.0
a AUC: area under the curve.
b LR: Likelihood ratio.
Please cite this article as: D. Azzopardi, A.T. Chew, A. Deierl, et al., Prospec
treatment with xenon..., EBioMedicine, https://doi.org/10.1016/j.ebiom.20that cerebralmagnetic resonance biomarkers, such as used in our study,
provide a rapid and accurate surrogate outcome that can be used
to identify useless interventions early and select promising neuroprot-
ectants for further study.
Neurological and neurodevelopmental outcomes at 2–3 years of age
were very similar in the xenon plus hypothermia and hypothermia only
groups, mirroring the closeness of the results between groups of the ce-
rebral biomarkers measured soon after birth, visual analysis of conven-
tional MRI and neurological assessment at hospital discharge in the
neonatal period. There was no difference in deaths and loss to follow-
up in the two randomised groups, so the randomisation property still
broadly applies to the 2–3-year outcomes, but this study was not de-
signed to detect an effect of xenon on neurodevelopmental outcomes
and was underpowered to do so because TOBY-Xe was powered to de-
tect changes in the cerebral biomarkers. However, the near identical re-
sults of the clinical outcomes in the two treatment groups, and the close
concordance with the neonatal outcomes suggest a low probability that
the results would materially change with a larger study.
The results also conﬁrm that a deﬁnitive clinical trial of xenon gas
combined with moderate hypothermia after birth asphyxia would notyears.
rs at 2–3 years
Sensitivity (%) Speciﬁcity (%) LRb+ LRb P value
54) 64.29 100.00 Inﬁnite 0.357 0.001
82) 66.67 93.18 9.777 0.357 0.001
00) 70.00 100.00 inﬁnite 0.300 0.002
ding deaths
00) 88.46 100.00 inﬁnite 0.153 b0.001
34) 81.82 77.27 3.600 0.253 b0.001
00) 80.95 95.24 17.006 0.200 b0.001
tive qualiﬁcation of early cerebral biomarkers in a randomised trial of
19.08.034
Fig. 5. Plot of Log Lac/NAA and post menstrual age in days at scan (N = 63).
8 D. Azzopardi et al. / EBioMedicine xxx (2019) xxxbe appropriate using the protocol deﬁned in the TobyXe study. The ab-
sence of a beneﬁcial effect of xenon could be for a number of reasons,
such as: suboptimal dose, duration and timing of administration of
xenon (the mean age of starting xenon in TOBY-Xe was almost 10 h);
the severity of encephalopathy in the participants; low sensitivity of
the cerebral biomarkers used in the study; and low power of the
follow-up study. Neuroprotective therapies are less likely to be success-
ful followingmore severe injury, as was demonstrated in a recent study
in animals that found no cerebral protection with xenon following a se-
vere asphyxial insult whilst previous studies found beneﬁcial effects fol-
lowingmilder injury [23]. However, it is unlikely that the TobyXe study
participants were more severely affected than infants recruited to the
successful large randomised trials of cooling since the eligibility criteria
of the TobyXe study were similar to those of the cooling trials, and the
mortality and severe disability rates did not differ greatly from that re-
ported in those trials [24].
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